

Clinical Data Receives Lilly Global Supplier Award

Newton, MA – September 3, 2008 –Clinical Data, Inc. (NASDAQ: CLDA) announced today that its Cogenics[®] division, the global leader in outsourced genomics services, has been recognized by Eli Lilly and Company for offering value-based genomics solutions that enable Lilly to create and sustain a competitive advantage.

Lilly Chief Executive Officer John Lechleiter noted Cogenics' exemplary contribution as an elite supplier of genomics solutions by conferring on Cogenics its 2008 Lilly Global Supplier Award, during a recent ceremony at Lilly's Indianapolis-based headquarters.

"Our scientists and associates work hard to deliver flexible, tailored genomics service solutions to all of our customers," said Clive Higgins, General Manager, North America for Cogenics. "Over the life of our engagement, Lilly has presented our team with a unique and interesting set of research challenges, and we are delighted that our solutions merit this exciting distinction."

Cogenics provides next generation sequencing, gene expression, clinical and non-clinical genotyping, biomanufacturing support and nucleic acid extraction and biobanking for both research and regulated environments. Cogenics has facilities in North Carolina, Texas, United Kingdom, France, and Germany.

Lilly selects Global Supplier Award recipients from among suppliers that have demonstrated exemplary relationship management, quality, service, speed and total efficiency. The Global Supplier Award is given annually to recognize "elite" suppliers for having a measurable impact on Lilly's objectives and priorities.

For more information about Cogenics and its genomic services offerings, please call 1-877-226-4364 (U.S.) or +49 (0) 8158 - 99 85-0 (E.U.) or email sales@cogenics.com.

About Cogenics

Cogenics, a division of Clinical Data, has established itself as a leading provider of value-based genomics solutions for both the Healthcare and Life Sciences industries. These solutions span the areas of current and next generation sequencing, gene expression, clinical and non-clinical genotyping, biomanufacturing support and nucleic acid extraction and biobanking, for both research and regulated environments. Cogenics combines operations from the acquisitions of Genaissance Pharmaceuticals, Lark Technologies (in the US and UK), Icoria, Genome Express (France) and Epidauros Biotechnologie (Germany). Its customers include some of the world's most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies. For more information, please visit www.cogenics.com.

About Clinical Data, Inc.

Clinical Data is a global biotechnology company unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare™. Its PGxHealth® division focuses on proprietary biomarker and pharmacogenetic test development as well as targeted therapeutics to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics® division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the company's website at www.clda.com for more information.

CONTACT INFORMATION:**EVC Group****Investors:**

Dahlia Bailey

650-305-1773

Doug Sherk

415-896-6820

Media:

Steve DiMattia

646-201-5445

General Business Inquiries

617-527-9933 x 3388

###